Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPICAL-1: Budesonide granules in mesalazine-refractory ulcerative colitis
NCT02550418Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Oct 2015
- Primary completion
- Mar 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of budesonide in ulcerative colitis (UC), sponsored by Dr. Falk Pharma GmbH. Started Oct 2015; status: completed.
02
Drugs
budesonide
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02550418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550418.